Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kelly Guerrero

Physician Assistant, Surgical Charleston, SC Physician Assistant

NPI 1699928556 CMS profile 10501627

316 Calhoun St, Ste 100, Charleston, SC 29401

Open in the dashboard

General payments

$4,749

146 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Guerrero of Charleston, SC is reported in the CMS Open Payments database as having received $4,749 across 146 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,219 42
2024 General $954 35
2023 General $697 39
2022 General $414 18
2021 General $465 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Guerrero
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Kelly Guerrero were reported at $2,219. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Kelly Guerrero Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $465 $111 $36–$285 $132
2022 $414 $126 $44–$350 $149
2023 $697 $137 $47–$355 $160
2024 $954 $146 $49–$384 $164
2025 $2,219 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $2,123 25 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $727 30 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $488 24 payments
  4. Scpharmaceuticals Inc. $302 14 payments
  5. Pfizer Inc. $277 13 payments
  6. Merck Sharp & Dohme Corporation $263 15 payments
  7. E.R. Squibb & Sons, L.L.C. $163 3 payments
  8. AstraZeneca Pharmaceuticals LP $128 8 payments
  9. Alnylam Pharmaceuticals Inc. $77 4 payments
  10. Lexicon Pharmaceuticals, Inc. $52 3 payments
  11. Other $150 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,650 140 payments
  2. Travel and Lodging $1,099 6 payments
Products named General payments · program years 2021–2025
  1. CARDIOMEMS Structural Heart $1,565 14 payments
  2. LifeVest $488 24 payments
  3. JARDIANCE Diabetes $451 17 payments
  4. VERQUVO $334 19 payments
  5. FUROSCIX $302 14 payments
  6. CARDIOMEMS Heart failure $301 4 payments
  7. VYNDAQEL $296 14 payments
  8. JARDIANCE Diabetes $276 13 payments
  9. MITRACLIP $192 4 payments
  10. CAMZYOS $142 2 payments
  11. Other $682 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,778

Median for Physician Assistant: 241

Drug cost

$495,187

Median for Physician Assistant: $4,110

Branded share of claims

40.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 379 $250,078
Furoscix Furosemide Brand 17 $109,210
Eliquis Apixaban Brand 95 $69,599
Entresto Sacubitril/Valsartan Brand 48 $33,170
Farxiga Dapagliflozin Propanediol Brand 29 $16,355
Bumetanide Generic 68 $2,614
Isosorbide Dinit-Hydralazine Isosorbide Dinit/Hydralazine Brand 13 $1,733
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 26 $1,725
Isosorbide Dinitrate Generic 33 $1,590
Potassium Chloride Generic 107 $1,551

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$43,821

Medicare's payments for the services billed

Medicare patients

217

Average age 79

Services billed

551

108 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Atrial fibrillation 70%
Arthritis 66%
Chronic kidney disease 65%
Diabetes 63%
COPD 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $180
$180 379 —
FUROSCIX
  • SCPHARMACEUTICALS INC. $132
$132 17 —
VYNDAQEL
  • PFIZER INC. $108
$108 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $71
$71 — —
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record